- 1. Individuals 18 to 49 years of age OR 65 to 85 years of age, inclusive on the day of informed consent.
- 2. Individuals with body mass index (BMI) between 18 and 32 kg/m2, inclusive, at screening .
- 3. Individuals who can comply with study procedures including follow-up .
Influenza, Human
Flucelvax (TIVc or QIVc) Pregnancy Registry
NCT03438487 | PHASE 1 | OBSERVATIONAL
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Syneos Health
Wilmington,North Carolina,United States,28405
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov